WILMINGTON – BioSpecifics Technologies Corp. announced Monday morning that it has entered into a merger deal with pharmaceutical giant Endo International PLC worth $540 million. As a small commercial-stage biopharmaceutical company, BioSpecifics develops injectable enzymes ...
© 2022 Delaware Business Times
Holiday flash sale! Subscribe to Delaware Business Times and save 50%.
Limited time offer. New subscribers only.